Part 1: Improving Risk-based Management Decisions in Follicular Lymphoma - a podcast by ReachMD

CME credits: 0.50

Valid until: 23-11-2021

Claim your CME credit at https://reachmd.com/cme/Oncology-and-Hematology/part-1-improving-risk-based-management-decisions-follicular-lymphoma/12009/

The anti-CD20 antibody rituximab has been the backbone of initial treatment for previously untreated follicular lymphoma (FL). The treatment options for FL are expanding, with multiple novel agents now approved by the US Food & Drug Administration in first-line and relapsed/refractory disease settings and others in late-stage trials. Despite advances in first-line care, treatment relapses commonly occur, with approximately 20% of patients experiencing relapse within 2 years; these patients have a 5-year overall survival of only 50%. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control, and thus early progression predicts poor prognosis.

A recent retrospective, exploratory analysis demonstrated the earlier the disease progression within the first 24 months (POD24), the higher the mortality risk, highlighting the need to identify patients at risk for early progression and who may benefit from first-line treatment that has demonstrated a relative risk reduction in early disease progression, such as obinutuzumab. These results represent important advances in the treatment of FL to reduce the rate of early disease progression. Disease and patient characteristics more commonly associated with higher POD24 have also been ...

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD